Last reviewed · How we verify
Depo-subQ Provera Injectable Product
At a glance
| Generic name | Depo-subQ Provera Injectable Product |
|---|---|
| Also known as | Depo, DMPA |
| Sponsor | University of Colorado, Denver |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Clinical and Biomarker Effects of Depot Medroxyprogesterone Acetate in Females With Sickle Cell Disease (PHASE4)
- Counseling Among Gender Diverse Adolescents Who Use Depot Medroxyprogesterone (PHASE4)
- Endometrial Biopsy in Progestin Contraceptive Users (EARLY_PHASE1)
- Postpartum Family Planning (PHASE4)
- Progesterone Containing Contraceptive Methods on Endogenous Progesterone Level
- Observation vs Progesterone Treatment for Management of Uterine Arteriovenous Malformation (PHASE4)
- A Study to Evaluate Injection Pain and Local Tolerability Following Subcutaneous (SC) Administration of TV-46046 (PHASE1)
- Effects of UCA-PSCs in Women With POF (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: